MET and neoplasm: These biological targets (e.g., receptor tyrosine kinases EGFR, c-Met, and non-receptor tyrosine kinase c-Src) are known to synergistically potentiate each other’s effects in driving tumor growth and provide a strong rationale for developing a multi-targeted approach against their adverse effects.